QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 my-top-biotech-stock-picks-and-portfolio-strategy-for-the-next-3-10-years

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...

 chardan-capital-maintains-buy-on-prime-medicine-lowers-price-target-to-10

Chardan Capital analyst Geulah Livshits maintains Prime Medicine (NASDAQ:PRME) with a Buy and lowers the price target from $...

 prime-medicine-q2-eps-041-misses-039-estimate-sales-1115m-beat-750000k-estimate

Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0....

 prime-medicine-announces-proposed-public-offering-of-common-stock-no-size-or-amount-disclosed

Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time cura...

 citigroup-downgrades-prime-medicine-to-neutral-lowers-price-target-to-15

Citigroup analyst Samantha Semenkow downgrades Prime Medicine (NASDAQ:PRME) from Buy to Neutral and lowers the price target ...

 jmp-securities-maintains-market-outperform-on-prime-medicine-lowers-price-target-to-6

JMP Securities analyst Silvan Tuerkcan maintains Prime Medicine (NASDAQ:PRME) with a Market Outperform and lowers the price ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION